Related Experiment Video
Updated: Apr 26, 2026
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Adenoma receptors and histologic characteristics determining management outcomes
Luiz Eduardo Wildemberg1,2, Mônica R Gadelha1,2,3
1Neuroendocrinology Research Center, Endocrinology Section, Medical School, and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
Abstract:
Patient responses to medical therapy for acromegaly are variable. Adenoma features, including histologic characteristics and receptor density, are closely associated with distinct clinical behavior and therapeutic outcomes. Densely granulated pure somatotropinomas respond more favorably to somatostatin receptor subtype 2 (SST2)-selective ligands (octreotide and lanreotide) compared with sparsely granulated adenomas. In contrast, sparsely granulated adenomas may respond more favorably to pasireotide, which has a higher affinity for somatostatin receptor subtype 5 (SST5). Expression levels of SST2 receptors are also associated with responsiveness to octreotide and lanreotide, whereas response to pasireotide is linked to higher SST5 expression. Recent prospective studies have highlighted that treatment strategies guided by biomarkers determining therapeutic response are more effective than standard, non-biomarker-based approaches. Current evidence supports the incorporation of biomarkers into decision-making for medical management of acromegaly, while these approaches are being further validated.
Insights
Acromegaly treatment varies. Biomarker-guided therapy, based on adenoma features and somatostatin receptor expression (SST2/SST5), improves patient response compared to standard approaches.
Area of Science:
- Endocrinology
- Oncology
Background:
- Patient responses to acromegaly medical therapy are variable.
- Adenoma characteristics influence clinical behavior and treatment outcomes.
Purpose of the Study:
- To investigate the association between adenoma features and therapeutic outcomes in acromegaly.
- To evaluate the role of biomarkers in guiding acromegaly treatment decisions.
Main Methods:
- Histologic analysis of adenoma characteristics.
- Assessment of somatostatin receptor subtype 2 (SST2) and 5 (SST5) expression.
- Correlation of receptor density with patient response to specific somatostatin analogs (octreotide, lanreotide, pasireotide).
Main Results:
- Densely granulated somatotropinomas respond better to SST2-selective ligands (octreotide, lanreotide).
- Sparsely granulated adenomas may respond better to pasireotide (higher SST5 affinity).
- SST2 receptor expression correlates with response to octreotide/lanreotide; SST5 expression correlates with pasireotide response.
Conclusions:
- Adenoma histology and somatostatin receptor expression are key biomarkers for predicting acromegaly treatment response.
- Biomarker-guided therapy offers improved outcomes over standard approaches.
- Further validation of biomarker-based strategies is recommended for acromegaly management.
Related Concept Videos
01:31Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
01:27Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:26Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...